Robotic knee replacement matches surgeon-only outcomes in major trial

Across the operating theaters of Britain, a quiet technological shift has been underway. Robotic arms now assist in one out of every seventeen knee replacements performed in the UK—a fraction compared to the United States, where the figure reaches one in six, or Australia, where nearly half of all such procedures now involve robotic guidance. The promise has been straightforward: machines can position artificial joints with a precision that human hands, however skilled, cannot quite match. They can adapt to the unique geometry of each patient's knee in ways conventional surgery struggles to achieve. But a landmark trial published this week in The Lancet suggests the story is more complicated than the technology's advocates hoped.

The RACER-Knee trial, the world's largest double-blind randomized controlled study of its kind, enrolled 339 patients across ten hospitals and tracked outcomes under the care of thirty-three surgeons. Half received conventional knee replacement surgery. Half received the same procedure assisted by the Stryker Mako robotic system, the most widely deployed platform globally. The researchers, led by Professor Andrew Metcalfe at the University of Warwick and supported by the National Institute for Health and Care Research, followed patients for a full year after surgery, measuring everything from pain levels to mobility to their subjective sense of how aware they were of their artificial joints during everyday life. The results were unambiguous: at twelve months, the two groups were essentially indistinguishable.

Patients in both arms reported similar pain in the hospital and in the first three months of recovery. Their ability to walk improved at comparable rates. Their scores on the Forgotten Joint Scale—a measure of how much patients notice their artificial knee during daily activities—showed no meaningful difference. Neither group required follow-up surgery at higher rates. The robotic system, in other words, did not deliver the clinical advantage its precision suggested it should. "We are very grateful for the support of the many patients who took part," Metcalfe said in a statement, "but for robotic-assisted knee replacements, there is still work to do before we see benefits such as less pain or better movement."

The trial did confirm what the engineers had promised: the robotic arm achieved superior precision in positioning the implant. It also proved safe—serious adverse events occurred at equivalent rates in both groups, suggesting the technology introduced no new risks. But precision alone, the data showed, does not automatically translate into better outcomes for patients. The procedures took longer, consuming an average of ten and a half additional minutes per operation. They cost substantially more, running approximately £950 higher per patient. Under current NHS cost thresholds, the robotic system failed the test of cost-effectiveness over the first year.

Professor Edward Davis, a consultant orthopedic surgeon at the Royal Orthopedic Hospital, offered a measured interpretation. "These results are by no means a condemnation of the robotic systems," he said, "but more understanding of the ideal position for a knee replacement and personalization for each patient is needed." The implication was clear: the technology may have been deployed before surgeons fully understood how to leverage its capabilities. The precision exists. The question is whether current surgical protocols are designed to use it in ways that actually benefit patients.

The researchers plan to continue following their cohort for a full decade, watching for differences that might emerge over time—particularly whether robotic assistance reduces the likelihood of revision surgery years down the line. That longer view may yet vindicate the technology. For now, though, the trial has delivered an uncomfortable message to an industry betting heavily on automation: being more precise is not the same as being better. The next phase of development will require not just better machines, but a deeper understanding of how to tailor those machines' capabilities to each patient's individual anatomy in ways that translate precision into tangible clinical benefit.